Asia Today: Hong Kong gets Pfizer vaccines as 2nd option
HONG KONG (AP) — Over 500,000 doses of the Pfizer-BioNTech vaccine arrived in Hong Kong on Saturday following a two-day delay due to export procedures, offering a second inoculation option for the city.
The Pfizer-BioNTech shots will be offered to about 2.4 million eligible residents from priority groups such as those aged 60 and above and health care workers.
The 585,000 doses of the vaccine — the first batch of the initial 1 million — arrived from Germany. The remaining doses will be delivered in early March, according to a government statement.
About 70,000 residents who have registered for Hong Kong’s vaccination program, which kicked off on Friday, will receive the shots developed by Chinese biopharmaceutical firm Sinovac. The Sinovac vaccines were the first to arrive last week.
About 6,000 people have already been injected with the Sinovac vaccine. Registration details for those wishing to receive the Pfizer-BioNTech shots haven't been announced yet.
Hong Kong has struck deals for a total of 22.5 million doses, with 7.5 million each from Sinovac, AstraZeneca and Fosun Pharma, which is delivering the Pfizer-BioNTech vaccines. The government has so far approved the Sinovac and Pfizer-BioNTech vaccines.
In other developments around the Asia-Pacific region:
— South Korea has reported another 405 coronavirus cases as it began vaccinating tens of thousands of workers at front-line hospitals in the second day of its mass immunization program. The daily increase reported by the Korea Disease Control and Prevention Agency on Saturday brought the national caseload to 89,321, including 1,595 deaths. Most of the new cases came from the densely populated Seoul metropolitan area, which was hit hardest by a devastating winter surge that erased months of hard-won...